Table 2.
Univariate and multivariate analyses of OS.
| Characteristics | Median OS | Univariate | Multivariate | ||
|---|---|---|---|---|---|
| (month) | HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Age (year) | 0.28 | ||||
| <60 | 15.3 | 1 | |||
| ⩾60 | 6.2 | 1.31 (0.81–2.12) | |||
| Gender | 0.77 | ||||
| Female | 6.1 | 1 | |||
| Male | 7.5 | 1.06 (0.73–1.54) | |||
| ECOG | <0.001 | <0.001 | |||
| 0–1 | 9.3 | 1 | 1 | ||
| ⩾2 | 3.0 | 2.76 (1.81–4.20) | 2.35 (1.52–3.64) | ||
| Bajorin risk score | <0.001 | ||||
| 0–1 | 8.4 | 1 | |||
| 2 | 2.2 | 3.33 (1.99–5.58) | |||
| Visceral metastasis | <0.001 | <0.001 | |||
| No | 12.5 | 1 | 1 | ||
| Yes | 3.7 | 2.05 (1.40–3.00) | 2.08 (1.41–3.08) | ||
| WBC (×103/μL) | <0.001 | 0.012 | |||
| <10 | 10.5 | 1 | 1 | ||
| ⩾10 | 2.9 | 2.94 (2.02–4.30) | 1.88 (1.15–3.08) | ||
| Hb (g/dL) | <0.001 | 0.008 | |||
| <10 | 3.7 | 1 | 1 | ||
| ⩾10 | 11.6 | 0.48 (0.33–0.69) | 0.59 (0.39–0.87) | ||
| NLR | <0.001 | 0.03 | |||
| <5 | 14.2 | 1 | 1 | ||
| ⩾5 | 3.7 | 3.30 (2.26–4.82) | 1.90 (1.06–3.40) | ||
| SII | <0.001 | 0.62 | |||
| Low (<2205) | 10.2 | 1 | 1 | ||
| High (⩾2205) | 2.8 | 2.93 (1.99–4.29) | 0.85 (0.46–1.58) | ||
| PLR | <0.001 | 0.50 | |||
| Low (<194.84) | 11.7 | 1 | 1 | ||
| High (⩾194.84) | 4.8 | 2.29 (1.57–3.33) | 1.21 (0.69–2.12) | ||
| PD-L1 | 0.25 | ||||
| <10 | 7.5 | 1 | |||
| ⩾10 | 12.3 | 0.76 (0.48–1.21) | |||
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; HR, hazard ratio; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; PD-L1, programmed cell death ligand-1; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammation index; WBC, white blood cell count.